HK Stock Market Move | CARSGEN-B (02171) fell more than 4%, expected net loss in the first half of the year not exceeding 80 million yuan, significantly narrowed compared to the same period last year.

CARSGEN-B (02171) fell by more than 4%, dropping 4.86% to HK$23.5 as of the time of writing, with a turnover of HK$36.08 million. On the news front, Kegui Pharmaceutical released a performance forecast, expecting a net loss in the first half of 2025 not exceeding HK$80 million, significantly narrowing from around HK$351 million in the same period last year; adjusted net loss excluding non-cash expenses such as stock incentives is expected to be no more than HK$75 million, also a substantial decrease year-on-year. The narrowing loss is mainly due to the commercialization revenue growth of the core product CT053 in mainland China, the positive impact of exchange rate fluctuations, and significant reduction in R&D expenses for CT053 and CT041. It is worth noting that on June 25th, the China National Medical Products Administration accepted a new drug marketing application (NDA) for Sorafenib Injection, used to treat advanced gastric/esophageal junction adenocarcinoma patients with Claudin18.2 positive expression who have failed at least second-line treatment. In addition, a summary of clinical trial results for Sorafenib Injection for adjuvant therapy in pancreatic cancer has been accepted for poster presentation at the 2025 European Society for Medical Oncology (ESMO) Annual Meeting.